Artiva Biotherapeutics, Inc. Common Stock (ARTV) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 1 years, Artiva Biotherapeutics, Inc. Common Stock has achieved a revenue compound annual growth rate (CAGR) of -99.3%, while earnings have grown at 127.6% CAGR.
Historical revenue and profitability trends for Artiva Biotherapeutics, Inc. Common Stock
The chart above illustrates Artiva Biotherapeutics, Inc. Common Stock's revenue trajectory over the past 1 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Artiva Biotherapeutics, Inc. Common Stock's business.
How efficiently Artiva Biotherapeutics, Inc. Common Stock converts revenue into profit
Profit margins reveal how much of each dollar of revenue Artiva Biotherapeutics, Inc. Common Stock retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Artiva Biotherapeutics, Inc. Common Stock to continue growing earnings in the coming year. The consensus analyst rating is 4.6667 based on 6 analysts.
Based on our comprehensive analysis, Artiva Biotherapeutics, Inc. Common Stock (ARTV) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Artiva Biotherapeutics, Inc. Common Stock's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Artiva Biotherapeutics, Inc. Common Stock stacks up against similar companies
Explore growth analysis for top stocks
Related: ARTV Valuation, ARTV Dividend, ARTV Financial Health
Compare: ARTV vs AAPL, ARTV vs MSFT, ARTV vs GOOGL